02 June 2017
: Case report
Follicular B Cell Lymphoma with Accompanying Ischemic Gastritis Completely Resolved by Rituximab
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Unexpected drug reaction , Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Anam Tariq1ABCDEFG*, Neal Mehta1EF, Kathryn Peroutka2DFDOI: 10.12659/AJCR.903506
Am J Case Rep 2017; 18:617-621
Abstract
BACKGROUND: Follicular B cell lymphomas account for a significant portion of all newly diagnosed non-Hodgkin’s lymphomas. While involvement can be varied, the most common extranodal presentation is within the gastrointestinal tract beyond the stomach. In addition, the stomach has a diffuse multivessel vascular supply, which decreases the likelihood of developing ischemic gastritis.
CASE REPORT: An 89-year-old woman with history of diabetes, deep venous thromboembolism, and hypertension was referred due to a newly diagnosed retroperitoneal mass. Biopsy of a left para-aortic node was consistent with low-grade follicular B cell lymphoma. Following mainstream treatment guidelines, rituximab was administered. Approximately 12 hours later, the patient presented to the Emergency Department with intractable vomiting and nausea. After admission, an esophagogastroduodenoscopy (EGD) revealed extensive ischemic gastritis. Due to recurrent ascites requiring frequent paracenteses, and the clinical aggressiveness of the patient’s underlying lymphoma, a second dose of rituximab was administered with concurrent initiation of total parenteral nutrition. Approximately 1 week later, the patient underwent a repeat EGD for quality of life planning while in hospice. The repeat EGD revealed resolved ischemic gastritis. Her diet was advanced and she was subsequently discharged home.
CONCLUSIONS: Rituximab alone shows promise in treating extensive follicular B cell lymphoma complicated by ischemic gastritis, which has not been previously reported in the literature.
Keywords: gastritis, Ischemia, Lymphoma, Follicular
SARS-CoV-2/COVID-19
04 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
In Press
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936585
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935885
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934951
05 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936165
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744